ZA927503B - Method for preventing allograft rejection. - Google Patents

Method for preventing allograft rejection.

Info

Publication number
ZA927503B
ZA927503B ZA927503A ZA927503A ZA927503B ZA 927503 B ZA927503 B ZA 927503B ZA 927503 A ZA927503 A ZA 927503A ZA 927503 A ZA927503 A ZA 927503A ZA 927503 B ZA927503 B ZA 927503B
Authority
ZA
South Africa
Prior art keywords
allograft rejection
preventing allograft
preventing
rejection
allograft
Prior art date
Application number
ZA927503A
Other languages
English (en)
Inventor
Mitsuaki Isobe
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of ZA927503B publication Critical patent/ZA927503B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA927503A 1991-10-01 1992-09-30 Method for preventing allograft rejection. ZA927503B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76804491A 1991-10-01 1991-10-01

Publications (1)

Publication Number Publication Date
ZA927503B true ZA927503B (en) 1993-05-03

Family

ID=25081356

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA927503A ZA927503B (en) 1991-10-01 1992-09-30 Method for preventing allograft rejection.

Country Status (8)

Country Link
EP (1) EP0610298A1 (fr)
JP (1) JPH07502727A (fr)
AU (1) AU667487B2 (fr)
CA (1) CA2120500A1 (fr)
HU (1) HUT69725A (fr)
MX (1) MX9205637A (fr)
WO (1) WO1993006864A1 (fr)
ZA (1) ZA927503B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ATE151642T1 (de) * 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
MX9305070A (es) * 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
WO2001051084A1 (fr) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnostic et traitement de troubles hepatiques inflammatoires par inhibition de la liaison de lfa-1 a icam-1
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
EP1419236A4 (fr) 2001-07-24 2005-08-03 Biogen Idec Inc Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
US7662921B2 (en) 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
CA2568570A1 (fr) 2004-06-09 2005-12-29 Genentech, Inc. Procede de traitement du granulome annulaire ou sarcoide
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (fr) * 1987-11-02 1994-12-07 Baylor College Of Medicine Utilisation du ICAM-1 ou de ses derivés fonctionels pour le traitement des inflammations non spécifiques
DE68923675T2 (de) * 1988-09-28 1996-02-15 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
CA2002860A1 (fr) * 1988-11-14 1990-05-14 Michael A. Gimbrone Anticorps specifiques de l'elam-1 et application
ES2035668T3 (es) * 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
WO1990013316A1 (fr) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination de cellules infectees par l'hiv-1
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method

Also Published As

Publication number Publication date
HUT69725A (en) 1995-09-28
HU9400930D0 (en) 1994-06-28
WO1993006864A1 (fr) 1993-04-15
MX9205637A (es) 1993-05-01
JPH07502727A (ja) 1995-03-23
AU2782992A (en) 1993-05-03
AU667487B2 (en) 1996-03-28
EP0610298A1 (fr) 1994-08-17
CA2120500A1 (fr) 1993-04-15

Similar Documents

Publication Publication Date Title
ZA917163B (en) Filtration arrangement and method.
HK1010191A1 (en) Method for manufacturing anti-viral compounds.
EP0656319A3 (fr) Procédé pour production de poudre d'alumine-alpha.
EP0605240A3 (fr) Appareil de focalisation automatique.
EP0655212A3 (fr) Machine automatique pour préparer des boissons.
EP0568269A3 (fr) Diode et méthode pour sa fabrication.
EP0663554A3 (fr) Bague avec patins de glissement et méthode pour sa fabrication.
EP0595233A3 (fr) Procédé de fabrication d'un semiconducteur sur isolant.
EP0625781A3 (fr) Appareil de montage.
ZA922313B (en) Anticoagulants and processes for preparing such.
EP0626410A3 (fr) Procédé pour la préparation de polycarbonates.
EP0604025A3 (fr) Procédé de formation d'images.
ZA927503B (en) Method for preventing allograft rejection.
EP0589725A3 (fr) Méthode thermosensible pour former des images.
ZA925463B (en) Method for the manufacture of tall oils.
EP0656067A4 (fr) Procedes de depistage d'agents immunosuppressifs.
EP0646846A3 (fr) Procédé de formation d'image.
EP0585529A3 (fr) Palier de support.
EP0607696A3 (fr) Procédé de traitement d'image.
ZA93782B (en) Determination method.
AU2323492A (en) Method for inhibiting allograft rejection
EP0644805A1 (fr) Machine-outil automatique travaillant par formage.
EP0599142A3 (fr) Méthode de fabrication d'immunoconjugués.
EP0578138A3 (fr) Méthode pour la détection de gènes.
EP0602841A3 (fr) Procédé de fabrication de circuits intégrés.